In the second part of our series, we compared peak drug sales estimates against the up-front payments in the deals as a proxy for commercial success
You may also be interested in...
There's no correlation between the up-front payment made in the deal and the peak sales for the drug that was the product of the deal. Second in a series of follow-ups to IN VIVO’s 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.